EIR Brochure Final 2 Paperturn - Flipbook - Page 15
ADAM HILL
CEO
Oncimmune
STEVE McCONCHIE
CEO
Aptus Clinical
MATTHEW REANEY
Head of Patient Centered Endpoints
IQVIA
PAUL COX
VP Global Commercial
Freeline Therapeutics
Adam M Hill MD PhD is a dualqualified Clinician and Mechanical
Engineer, with a career built at the
interface of Industry, Academia and
Health systems. Over the last 2
decades, he has trained in Surgery in
the British Army; provided growth
strategy and investment advice to
life science companies on behalf of
the British Government; led the
global medical function of a
multinational; pivoted an automotive
company into servicing the
regulated health technology sector;
and recently led a public listed
diagnostics company.
Steve has nearly 30 years of hands
on clinical drug development
experience including 25 years with
AstraZeneca, where he gained
valuable global experience delivering
numerous oncology and
haematology clinical development
programmes with small molecules
and biologics. Steve co-founded
Aptus Clinical where he and his
expert teams have continued to
support the design, conduct and
delivery of innovative early phase
clinical studies for a broad range of
life science and biotech clients.
Matthew is a Chartered and
Practitioner Health Psychologist, a
Chartered Scientist, a Fellow of
both the Royal Societies of
Medicine and Public Health, and an
Associate Fellow of the British
Psychological Society. Matt is
currently the Head of the PatientCentered Endpoint Scientific and
Analytic teams at IQVIA, and a
Guest Lecturer on the psychology
program at Royal Holloway
University of London
Paul is currently Vice President at
Freeline Therapeutics and is leading
the development of a new
commercial function at Freeline
following its recent IPO. He has 25+
years of pharmaceutical commercial
experience including launching
multiple pharmaceuticals into usually
highly competitive environments. His
commercial career evolved from
launching new medical devices into
specialist therapies and rare disease
product launch as well as gene
therapies.
Adam can advice on:
Diagnostics.
Spin-outs creation.
Identify commercial and
investement opportunities.
Steve can advise on:
Clinical drug development,
particularly in oncology and cell
therapies.
Use of biomarker in clinical
trials.
Career development for early
career researchers.
Matthew can advise on:
The selection, development,
implementation, validation
and interpretation of clinical
outcome assessment tools
for research and routine
clinical practice.
Technology to improve the
health of people with acute
and chronic conditions.
Paul can advise on:
Global commercial strategy.
Commercial and competitive
landscape assessment for
early-stage therapies.
Market and patient access
requirements and how to build
this in early.